Olanzapine Treatment and Weight Gain: Considering the Lipid Side Effects of Antipsychotics

Balf, Gabriela

doi:10.1176/appi.ajp.2008.08040526

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, those with a pre-disposition to developing metabolic syndrome may have already done so by the time they reach old age. It is possible that the 20-25 year reduction in life span for people with schizophrenia (Newman and Bland, 1991;Harris and Barraclough, 1998), which is largely attributed to cardiovascular disease (Marder et al, 2004;Balf, 2008), means that the majority of those who are pre-disposed to metabolic diseases are not even reaching old age (Guenette et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Metabolic side effects of atypical antipsychotics in older adults

Chacko

Boyd

Murphy

2018

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic side effects of atypical antipsychotics in older adults

Chacko

Boyd

Murphy

2018

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2009

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly

et al. 2014

View full text Add to dashboard Cite

The metabolic side effects of atypical antipsychotics (AAPs) have been widely studied in younger populations, but research investigating these sequelae in the elderly is lacking. This article reviews the available literature examining the use of AAPs in the elderly, evaluating their association with weight gain and changes in blood glucose and lipid parameters. We find a relative paucity of studies in this area; while some data highlight significant, collective changes in metabolic parameters, the majority suggests an apparent low vulnerability to these side effects. We conclude that the risk and clinical implications of unfavorable metabolic changes in the elderly being treated with AAP medications remain largely undetermined, and we caution against drawing firm conclusions based on the available data. The conflicting evidence leaves us recommending that metabolic monitoring be implemented, with regular follow-up as advocated in other populations.

show abstract

Olanzapine Treatment and Weight Gain: Considering the Lipid Side Effects of Antipsychotics

Cited by 4 publications

References 9 publications

Metabolic side effects of atypical antipsychotics in older adults

Metabolic side effects of atypical antipsychotics in older adults

Current awareness: Pharmacoepidemiology and drug safety

Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly

Contact Info

Product

Resources

About